42807-42-1

Basic information

• Product Name: 1-Butanol, 3-methyl-2-[(phenylmethyl)amino]-, (2S)-
• CAS NO: 42807-42-1
• Molecular Formula: C12H19NO
• Molecular Weight: 193.289
• Mol File: 42807-42-1.mol
• Article Data: 31

Chemical Properties

• CAS DataBase Reference: 1-Butanol, 3-methyl-2-[(phenylmethyl)amino]-, (2S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Butanol, 3-methyl-2-[(phenylmethyl)amino]-, (2S)-(42807-42-1)
• EPA Substance Registry System: 1-Butanol, 3-methyl-2-[(phenylmethyl)amino]-, (2S)-(42807-42-1)

Safety Data

• Hazardous Substances Data: 42807-42-1(Hazardous Substances Data)

Upstream product

• 57463-16-8 ethyl (S)-N-benzylvalinate 
• 2901-80-6 N-benzoyl-L-valine 
• 16652-76-9 L-valine benzyl ester p-toluenesulfonate salt 
• 93-97-0 benzoic acid anhydride 
• 102720-25-2 (S)-1-((tert-butyldimethylsilyl)oxy)-3-methylbutan-2-amine 
• 100-52-7 benzaldehyde 
• 4070-48-8 L-Valine methyl ester 
• 72-18-4 L-valine 
• 98-88-4 benzoyl chloride 
• 6306-52-1 L-valine methylester hydrochloride 
• 2026-48-4 (S)-valinol 
• 100-39-0 benzyl bromide 
• 121328-33-4 3-benzyl-(4S)-isopropyl-1,3-oxazolidin-2-one 
• 84983-97-1 N-benzylidene-L-valinol 

Downstream Products

• 123054-04-6 (1'S,2S,4S)-3-benzyl-2-<1'-(dibenzylamino)-2'-phenylethyl>-4-(methylethyl)-1,3-oxazolidine 
• 123054-04-6 (1'R,2RS,4S)-3-benzyl-2-<1'-(dibenzylamino)-2'-phenylethyl>-4-(methylethyl)-1,3-oxazolidine 
• 188593-98-8 (S)-(-)-2-(Benzylideneamino)-3-methyl-1-butanol N-oxide 
• 121328-33-4 3-benzyl-(4S)-isopropyl-1,3-oxazolidin-2-one 
• 1268883-26-6 (4S)-2-oxo-3-benzyl-4-isopropyl-1,2,3-oxathiazolidine 
• 214911-99-6 (S)-2-[(2-Benzenesulfonyl-allyl)-benzyl-amino]-3-methyl-butan-1-ol 
• 129156-92-9 N-benzyl-N-[(1S)-1-(methoxymethyl)-2-methylpropyl]amine 
• 148759-64-2 (S)-(+)-2-Allyl(benzyl)amino-3-methyl-1-butanol 
• 2026-48-4 (S)-valinol 
• 123054-05-7 (1'S,2S,4S)-3-benzyl-2-<1'-(dibenzylamino)ethyl>-4-(methylethyl)-1,3-oxazolidine 
• 138075-99-7 (2R,4S)-2-vinyl-1,3,2-oxapospholidin-2-one 
• 131570-77-9 Methyl (E)-3-<4(S)-3-Benzyl-4-isopropyloxazolidin-2-yl>propenoate 
• 158554-90-6 (S)-3-Benzyl-4-isopropyl-thiazolidine-2-thione 
• 263262-57-3 C₁₂H₁₇N 

Relevant articles and documents

Synthesis of chiral monoaza-15-crown-5 ethers from L-valinol and the enantiomeric recognition of chiral amines and their perchlorates salts

A practical synthesis of chiral monoaza-15-crown-5 ethers 1 and 2 has been achieved from L-valinol. The molecular recognition by these chiral crown ethers for (RS)-α-phenylethylamine, (RS)-α-(1-naphthyl)ethylamine and their perchlorate salts has been characterized by UV-vis.

Synthesis of β-Hydroxy-α,α-difluorosulfonamides from Carbanions of Difluoromethanesulfonamides

The synthesis of β-hydroxy-α,α-difluorosulfonamides was achieved by reacting difluoromethanesulfonamides with KHMDS in the presence of an aldehyde or ketone. The reaction exhibited a dramatic counterion effect with KHMDS or NaHMDS usually giving excellent yields in minutes, while lithium bases gave little or no product. Excellent yields and high diastereomeric ratios were achieved with Nα-benzyl-Nα-phenylfluorenyl (PhF)-protected chiral amino aldehydes derived from amino acids. Following deprotection, a β-hydroxy-α,α-sulfonamide reacted under peptide coupling and Mitsunobu conditions to furnish a peptidomimetic in an excellent overall yield.

Discovery of APD371: Identification of a Highly Potent and Selective CB2 Agonist for the Treatment of Chronic Pain

The discovery of a novel, selective and fully efficacious CB2 agonist with satisfactory pharmacokinetic and pharmaceutical properties is described. Compound 6 was efficacious in a rat model of osteoarthritis pain following oral administration and, in contrast to morphine, maintained its analgesic effect throughout a 5-day subchronic treatment paradigm. These data were consistent with our hypothesis that full agonist efficacy is required for efficient internalization and recycling of the CB2 receptor to avoid tachyphylaxis. Based on its overall favorable preclinical profile, 6 (APD371) was selected for further development for the treatment of pain.